Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30989325 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL19212517 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL30989302 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL1246014 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3765567 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL30989337 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL30989339 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL21810753 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL21810763 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13685928 | 1.00 | CA12 (0.43) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359595-A | Nitric oxide donor type atrasentan derivative, and pharmaceutical composition and application thereof | 江苏海洋大学 | 2024-07-19 | — | — | CN | claimed |
| CN-118359546-A | Nitric oxide donor type ambrisentan derivative, and pharmaceutical composition and application thereof | 江苏海洋大学 | 2024-07-19 | — | — | CN | claimed |
| CN-118359595-A | Nitric oxide donor type atrasentan derivative, and pharmaceutical composition and application thereof | 江苏海洋大学 | 2024-07-19 | — | — | CN | disclosed |
| CN-118359546-A | Nitric oxide donor type ambrisentan derivative, and pharmaceutical composition and application thereof | 江苏海洋大学 | 2024-07-19 | — | — | CN | disclosed |
| US-20100312003-A1 | METHOD FOR THE PREPARATION OF ORGANIC NITRATES | LONZA LTD. (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2048129-A1 | Method for the preparation of organic nitrates | LONZA AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| EP-0361888-B1 | Apovincaminic acid derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1994-05-04 | — | — | EP | disclosed |
| US-4980474-A | For treatment of vascular injuries, angina pectoris, hypertension and alzheimer*s disease | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1990-12-25 | — | — | US | disclosed |
| EP-0361888-A2 | Apovincaminic acid derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100312003-A1 | METHOD FOR THE PREPARATION OF ORGANIC NITRATES | NOS2, NOS1, NOS3 | CA12 1295/4885CA1 1071/4885CA2 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.